Filing Analysis
Shattuck Labs, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2026. The filing serves as a formal announcement of earnings via a press release furnished in Exhibit 99.1.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026.
- Filing date: August 11, 2026.
- The filing includes the announcement of financial results via press release (Exhibit 99.1).
- The information under Item 2.02 is furnished rather than filed for purposes of Section 18 liability.
Shattuck Labs, Inc. entered into an underwriting agreement on June 9, 2026, to sell 10,879,376 shares of common stock and 7,870,624 pre-funded warrants at a public offering price of approximately $4.00 per share. The underwriters also fully exercised an over-allotment option for an additional 2,812,500 shares on June 10, 2026.
🚩 Red Flags
- Significant dilution: The issuance of over 21 million potential shares (including warrants and over-allotment) will dilute existing shareholders.
- Use of pre-funded warrants often indicates that institutional investors are capping their ownership to avoid SEC beneficial ownership reporting requirements (5% threshold).
📋 Key Facts
- Offering price: $4.00 per share for common stock; $3.9999 per share for pre-funded warrants.
- Total common shares issued: 10,879,376 shares.
- Total pre-funded warrants issued: 7,870,624 shares.
- Underwriters' over-allotment option of 2,812,500 shares was exercised in full on June 10, 2026.
- Pre-funded warrants have a $0.0001 exercise price and are subject to beneficial ownership limits (4.99% or 9.99%).
- Expected closing date of the offering is June 11, 2026.
Shattuck Labs announced positive Phase 1 data for its lead candidate SL-325, demonstrating a favorable safety profile and low immunogenicity. The company also provided a timeline for its Phase 2b trial in Crohn's disease and reported significant proceeds from warrant exercises.
📋 Key Facts
- Phase 1 trial of SL-325 (n=72) showed complete DR3 occupancy at doses of 0.1 mg/kg and higher.
- Immunogenicity was low, with anti-drug antibodies (ADA) detected in only 3.7% (2/54) of participants.
- No serious treatment-emergent adverse events (TEAEs) were reported; all TRAEs were Grade 1.
- Initiation of RECEPTIVE-CD1 Phase 2b trial for Crohn's disease is expected in Q3 2026, with primary endpoint data expected in H1 2028.
- IND filing for bispecific candidate SL-846 is expected in the first half of 2027.
- The company expects to receive approximately $49.3 million in additional gross proceeds from the exercise of 45.4 million warrants.
Shattuck Labs, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 28, 2026. Key outcomes included the election of directors, ratification of KPMG LLP as the auditor, and the approval of an amended 2020 Equity Incentive Plan.
📋 Key Facts
- Annual Meeting held on May 28, 2026.
- Stockholders approved the amendment and restatement of the 2020 Equity Incentive Plan, increasing available shares by 1,691,082 and extending the term to March 23, 2036.
- Director nominees Taylor Schreiber, Helen M. Boudreau, and Clay Siegall were elected.
- KPMG LLP was ratified as the independent auditor.
- Stockholders voted to maintain an annual frequency for advisory votes on executive compensation.
- As of April 2, 2026, there were 75,581,787 shares of common stock entitled to vote.
Shattuck Labs, Inc. reported its financial results for the first quarter ended March 31, 2026. The results were announced via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on May 7, 2026, to report financial results for the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results was included as Exhibit 99.1.
- The information in the filing is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Shattuck Labs, Inc. reported its financial results for the fiscal year ended December 31, 2025. The announcement was made via a press release furnished as an exhibit to the filing on March 5, 2026.
📋 Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
- The report was signed by CEO Dr. Taylor Schreiber on March 5, 2026.
Shattuck Labs, Inc. has announced the date for its 2026 Annual Meeting of Stockholders and provided revised deadlines for stockholder proposals and director nominations.
📋 Key Facts
- The 2026 Annual Meeting is scheduled for Thursday, May 28, 2026.
- Stockholder proposals under SEC Rule 14a-8 must be received by the close of business on February 15, 2026.
- Director nominations and other stockholder proposals must be received between January 28, 2026, and February 27, 2026.
- The meeting date is more than 30 days before the anniversary of the prior annual meeting, necessitating revised deadlines.
Shattuck Labs, Inc. has entered into an 'at-the-market' (ATM) sales agreement with Leerink Partners LLC to facilitate the potential sale of up to $75 million in common stock.
🚩 Red Flags
- Potential significant dilution for existing shareholders due to the $75M equity issuance capacity.
- The use of proceeds for 'working capital' often indicates a need for immediate liquidity in micro-cap biotech firms.
📋 Key Facts
- Entered into a Sales Agreement with Leerink Partners LLC on January 22, 2026.
- The offering is for up to $75,000,000 of the Company's common stock.
- Sales will be conducted via an 'at-the-market' (ATM) offering at market prices.
- Agent commission is set at up to 3.0% of gross sales price.
- Proceeds are intended for clinical trials, product candidate development, working capital, and general corporate purposes.
This is an 8-K/A (Amendment No. 1) filed to correct typographical errors in a previously filed 8-K from the same date. The filing also references the company's quarterly financial results for the period ended September 30, 2025.
🚩 Red Flags
- None identified in this amendment; it is purely administrative/corrective.
📋 Key Facts
- Filed as an amendment (8-K/A) to correct typographical errors in the Original 8-K filed on November 6, 2025.
- The filing incorporates a press release regarding financial results for the quarter ended September 30, 2025.
- Company is an Emerging Growth Company.
Shattuck Labs, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025 via a press release.
📋 Key Facts
- The filing is a standard disclosure of quarterly financial results (Item 2.02).
- Results pertain to the quarter ended June 30, 2025.
- The associated press release was originally dated August 14, 2025.
Shattuck Labs, Inc. has completed a securities purchase agreement with institutional investors, resulting in significant board restructuring. The company appointed two new directors—one an OrbiMed designee and one an independent designee—following the resignation of four existing directors.
🚩 Red Flags
- Significant board turnover (4 resignations) coinciding with a major securities transaction.
- Board size reduction suggests restructuring following capital infusion/dilution event.
- OrbiMed's significant ownership (>15%) grants them substantial control over board composition.
📋 Key Facts
- Closing of a securities purchase agreement on August 25, 2025, with institutional accredited investors.
- Four directors resigned: Tyler Brous, Dr. Carrie Brownstein, Michael Lee, and Dr. Kate Sasser (none due to disagreements).
- Board size reduced from nine to seven members.
- Appointed Dr. Daniel Baker as an Independent Director Designee.
- Appointed Dr. Mona Ashiya as an OrbiMed Designee.
- OrbiMed holds >15% of outstanding common stock, granting them rights to designate up to two directors.
- New directors received 66,300 stock options each, vesting over three years.
Shattuck Labs, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Company is an emerging growth company.
Shattuck Labs entered into a securities purchase agreement to conduct a private placement of common stock and warrants, aiming to raise approximately $46 million in upfront gross proceeds. The deal is contingent upon FDA clearance of the SL-325 Investigational New Drug Application.
🚩 Red Flags
- Significant potential dilution: Total shares issuable via warrants could exceed 52 million, significantly increasing the float.
- Contingent closing: The deal depends on FDA clearance of SL-325, creating execution risk for the capital raise.
- Board seat concessions: Purchasers gaining board designation can lead to shifts in corporate control/governance.
📋 Key Facts
- Private placement of 15,225,158 shares of common stock and various pre-funded/common warrants.
- Combined price per Share and Common Warrant is $0.8677; Pre-Funded Warrant and Common Warrant is $0.8676.
- Expected upfront gross proceeds: ~$46 million (before fees).
- Potential additional gross proceeds of ~$57 million if all Common Warrants are exercised.
- Common Warrants have an exercise price of $1.0846 and expire 30 days after public announcement of Phase 1 clinical trial data for SL-325.
- Closing is contingent upon FDA clearance of the SL-325 Investigational New Drug Application.
- Certain Purchasers have the right to designate directors to the Board at Closing.
Shattuck Labs, Inc. held its 2025 Annual Meeting of Stockholders on July 10, 2025. The company successfully elected all Class II Director nominees and ratified KPMG LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on July 10, 2025.
- Record date for voting was May 14, 2025, with 47,903,215 shares entitled to vote.
- Neil Gibson, Ph.D., George Golumbeski, Ph.D., and Kate Sasser, Ph.D. were all elected as Class II Directors.
- KPMG LLP was ratified as the Independent Auditor with 41,016,269 votes in favor.
Shattuck Labs, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- The filing is a standard earnings announcement under Item 2.02.
- Financial results pertain to the quarter ending March 31, 2025.
- The company is an 'Emerging Growth Company' as defined by the SEC.
Shattuck Labs, Inc. filed an 8-K to announce its financial results for the three months and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 27, 2025
- Reporting period: Three months and year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Company is an emerging growth company.
Shattuck Labs, Inc. filed an 8-K to announce its financial results for the quarterly period ended September 30, 2024.
📋 Key Facts
- The filing was made on November 14, 2024.
- The report pertains to the quarter ended September 30, 2024.
- Financial results were released via a press release (Exhibit 99.1).
- The company is an emerging growth company.
Shattuck Labs is undergoing significant restructuring, including the termination of a collaboration agreement with Ono Pharmaceutical and the discontinuation of its SL-172154 program. The company will reduce its workforce by approximately 40% to prioritize its DR3 program.
🚩 Red Flags
- Termination of a material collaboration agreement with Ono Pharmaceutical.
- Discontinuation of a clinical development program (SL-172154) due to poor survival data readouts.
- Significant workforce reduction (40% of staff) indicating strategic pivot or cost-cutting necessity.
- Multiple 8-K items in a single filing (Items 1.02, 2.05, and 8.01).
📋 Key Facts
- Termination of Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd. (originally dated Feb 13, 2024).
- Discontinuation of the SL-172154 program following unfavorable survival data in MDS and AML studies.
- Workforce reduction impacting approximately 40% of Shattuck's employees.
- Expected restructuring charges between $1.5 million and $1.75 million, primarily for severance, to be recognized in Q4 2024.
- Cash, cash equivalents, and investments totaled approximately $105.3 million as of June 30, 2024.
Shattuck Labs, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: August 1, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'Emerging Growth Company'
Shattuck Labs, Inc. issued a press release containing updated positive interim clinical data from its Phase 1B dose expansion trial of SL-172154 in combination with azacitidine for high-risk MDS and TP53 mutant AML patients.
📋 Key Facts
- Released updated positive interim data on June 14, 2024.
- Trial focus: Phase 1B dose expansion of SL-172154 with azacitidine.
- Target patient populations: Frontline higher-risk myelodysplastic syndromes (MDS) and TP53 mutant acute myeloid leukemia (AML).
This is an amendment to a previous 8-K filing regarding the appointment of two new directors. The company has now assigned these individuals to specific Board committees.
📋 Key Facts
- Effective June 11, 2024, Dr. Kate Sasser was appointed to the Nominating and Corporate Governance Committee.
- Effective June 11, 2024, Dr. Clay Siegall was appointed to the Compensation Committee.
- The filing serves as an amendment (8-K/A) to a March 4, 2024, announcement regarding the initial appointment of these directors.
Shattuck Labs, Inc. held its 2024 Annual Meeting of Stockholders on June 7, 2024. The meeting resulted in the successful election of all Class I director nominees and the ratification of KPMG LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 7, 2024.
- Tyler Brous elected to the Board (35,243,095 votes for).
- Carrie Brownstein, M.D. elected to the Board (31,974,536 votes for).
- Michael Lee elected to the Board (31,970,466 votes for).
- KPMG LLP ratified as Independent Auditor with 41,479,667 votes in favor.
Shattuck Labs, Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2024.
📋 Key Facts
- The filing is a routine announcement of quarterly earnings (Item 2.02).
- Financial results pertain to the quarter ended March 31, 2024.
- The company is an 'Emerging Growth Company' as defined by the SEC.
Shattuck Labs, Inc. announced the expansion of its Board of Directors with the appointment of two new non-employee directors: Dr. Kate Sasser and Dr. Clay Siegall.
📋 Key Facts
- Dr. Kate Sasser appointed as Class II director effective March 1, 2024; she currently serves as CSO of Tempus AI.
- Dr. Clay Siegall appointed as Class III director effective March 1, 2024; he is the CEO and Chairman of Immunome, Inc. and co-founder of Seagen Inc.
- Both directors will serve until their respective successor elections at future Annual Meetings of Stockholders.
- Directors are to be compensated under the Company's non-employee director compensation policy.
Shattuck Labs, Inc. filed an 8-K to announce its financial results for the three months and fiscal year ended December 31, 2023.
📋 Key Facts
- The filing reports on earnings/financial condition (Item 2.02).
- Reporting period covers the three months and full year ended December 31, 2023.
- Results were announced via press release dated February 29, 2024.
Shattuck Labs, Inc. entered into a collaboration and license agreement with Ono Pharmaceutical Co., Ltd to research and develop bifunctional fusion proteins. The deal includes upfront/milestone payments of up to $9 million for the research phase and potential milestone/royalty payments totaling over $217.5 million if options are exercised.
🚩 Red Flags
- Ono has the right to terminate the agreement at any time with 90 days' notice (though they must cover costs incurred).
📋 Key Facts
- Collaboration effective date: February 13, 2024.
- Ono Pharmaceutical Co., Ltd granted an exclusive option to license products derived from the 'Development Compounds'.
- Shattuck is entitled to up to $9 million in upfront and research milestone payments.
- Ono will cover all of Shattuck's costs and expenses related to the Research Plan.
- Potential milestone/licensing payments if option is exercised: up to $217.5 million.
- Royalties range from mid-single digits to low double digits on global net sales for a maximum of 10 years per product.